Oruka Therapeutics, Inc. (ORKA)
WatchA data-driven read of ORKA's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
Signals are mixed: 4 of 5 available lean bullish, 1 lean bearish.
Every trading day in the last 2 years where ORKA moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 28, 2026 | -5.59% | $91.14 |
| Aug 24, 2026 | -5.13% | $102.42 |
| Aug 20, 2026 | -4.40% | $104.86 |
| Aug 10, 2026 | +6.40% | $105.14 |
| Jul 30, 2026 | +11.12% | $97.86 |
| Jul 17, 2026 | +11.63% | $92.70 |
| Jul 16, 2026 | -4.17% | $83.04 |
| Jul 9, 2026 | +4.59% | $88.27 |
| Jul 2, 2026 | -8.66% | $85.21 |
| Jun 26, 2026 | +4.58% | $90.60 |
| Jun 25, 2026 | +5.53% | $86.63 |
| Jun 22, 2026 | +18.03% | $85.38 |
| Jun 17, 2026 | +4.68% | $70.88 |
| Jun 11, 2026 | +6.93% | $68.47 |
| Jun 10, 2026 | -4.33% | $64.03 |
| Jun 9, 2026 | +4.48% | $66.93 |
| Jun 8, 2026 | +6.52% | $64.06 |
| Jun 4, 2026 | +8.88% | $62.28 |
| Jun 1, 2026 | -6.01% | $55.01 |
| May 20, 2026 | +5.51% | $60.67 |
| May 18, 2026 | -5.80% | $58.34 |
| May 7, 2026 | -8.20% | $64.07 |
| May 4, 2026 | +6.20% | $66.46 |
| May 1, 2026 | -8.52% | $62.58 |
| Apr 29, 2026 | -7.96% | $68.10 |
Showing the 25 most recent of 172 on record. Full history is on the Price Insights page.
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
855 Oak Grove Avenue, Menlo Park, CA, 94025, United States, 650 606 7910
Other Biotechnology companies tracked on this site, ranked by institutional ownership. Compare ORKA against its closest peers.
A complete statistical profile built from ORKA's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.